Merck beats on revenue boosted by Keytruda sales, but posts quarterly loss due to Prometheus deal

Shares of Merck are down roughly 4% this year, with a market value of roughly $270 billion, making it the third largest pharmaceutical company based in the U.S.

from Health and Science https://ift.tt/QFkGL12
https://ift.tt/3gPL9Fl
https://ift.tt/xa2lnpG